In a retrospective study performed by De Marchi et al.,18 investigating the use of CPS and TPS in 56 patients with NSCLC who received an ICI regimen including both monotherapy and combination therapies, the authors concluded that both TPS and CPS proved to be equally predictive of response to anti–programmed cell death protein 1/PD-L1 therapy. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.